CVS vs OPCH: Which Is the Better Buy in 2026?
Last updated October 2026
Short answer
CVS is the larger of the two ($118.13B market cap): the incumbent the market prices for continued execution (10.82x forward earnings, beta 0.60). OPCH is the smaller challenger ($4.67B), actually pricier on forward earnings (14.98x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
CVS vs OPCH: the tie-breaker metrics
Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | CVS | OPCH | What it tells you |
|---|---|---|---|
| Market cap | $118.13B | $4.67B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 10.82 | 14.98 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 24.31 | 23.64 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.60 | 0.58 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 56% of range | 70% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.48 | 3.71 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: CVS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how CVS and OPCH affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CVS and OPCH share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CVS and OPCH exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does CVS Health (CVS) do?
CVS Health runs three reporting segments. Health Care Benefits is the Aetna insurance business, which earns premiums from roughly 26 million medical members and profits when claims (the medical benefit ratio) stay below what it collects. Health Services is built around the Caremark pharmacy benefit manager, which negotiates drug prices and manages pharmacy claims for health plans and employers and generated over $48 billion of revenue in Q1 2026. Pharmacy and Consumer Wellness is the familiar retail footprint of CVS drugstores, which makes money filling prescriptions and selling front-of-store health and consumer goods, with same-store prescription volumes up nearly 7% in Q1 2026.
What does Option Care Health (OPCH) do?
Option Care Health (Nasdaq: OPCH) delivers medications through intravenous and other infusion therapies in patients' homes and at alternate-site suites, covering both acute needs (like post-hospital antibiotics and nutrition) and chronic conditions (such as immune, neurologic, and inflammatory diseases). It runs a nationwide network of pharmacies and nursing infrastructure, partners with drug manufacturers for distribution, and contracts with payers and health systems, making it the largest standalone player in a fragmented home-infusion market where the top few providers hold roughly a third of share.
CVS vs OPCH: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- CVS drivers: Integrated model under one roof; Turnaround and improving Aetna margins.
- OPCH drivers: The pending CD&R and McKesson take-private; Acute infusion demand and hospital partnerships.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The clearest risk is the medical-cost trend at Aetna: if claims reaccelerate, especially in Medicare Advantage, earnings can fall faster than premiums can be re-priced, which is what drove the 2023 to 2024 decline. For OPCH, the central risk is deal risk.
CVS or OPCH: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CVS if you believe its drivers more; OPCH if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CVS and OPCH guides.
CVS vs OPCH: the full fundamentals
CVS. CVS trades near 11x forward earnings and about 0.3x sales, a low multiple versus the broad market that reflects lingering caution after the 2023 to 2024 Aetna downturn and continuing PBM and legal risk rather than current results, which have beaten estimates four quarters running. Q3 2026 results are scheduled for November 4, 2026, with consensus adjusted EPS near $1.65 on ~$105 billion of revenue. Figures are approximate and tied to the asOf date; verify live quotes and the latest filings before acting.
OPCH. OPCH's valuation is now set by the $32.05 cash offer rather than by earnings multiples. At a close near $31.27 on October 16, 2026, the stock trades about 2.5% below the deal price, a spread that reflects time to closing and the risk the transaction is blocked or voted down. Option Care withdrew its 2026 guidance on announcing the deal, so the earlier profit targets no longer apply.
Headline figures (approximate, October 2026): CVS shows revenue (ttm) ~$413 billion (Q2 2026 ~$106B, up ~7% YoY), adjusted eps Q2 2026 $2.58 vs $1.85 estimate; 2026 consensus ~$8.04, 2027 ~$8.54, net income (ttm) ~$4.9 billion (net margin ~1.2%), aetna medical benefit ratio (q1 2026) ~84.6%, improved from ~87.3% a year earlier; OPCH shows deal price $32.05 per share in cash (CD&R and McKesson), deal value ~$5.8B including debt, expected close First half of 2027, revenue (ttm) ~$5.69B (~+2% YoY in Q2 2026).
The bottom line: CVS vs OPCH
CVS and OPCH are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CVS and OPCH exposure against your real portfolio. It is not an investment adviser.
Wondering how CVS or OPCH fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in CVS Health with AI
Connect the broker you already use and ask Walnut's AI how CVS fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between CVS and OPCH?
+
CVS Health runs three reporting segments. Option Care Health (Nasdaq: OPCH) delivers medications through intravenous and other infusion therapies in patients' homes and at alternate-site suites, covering both acute needs (like post-hospital antibiotics and nutrition) and chronic conditions (such as immune, neurologic, and inflammatory diseases). They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is CVS or OPCH the better stock?
+
Neither is universally better. CVS is the larger incumbent; OPCH is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, CVS or OPCH?
+
On forward P/E (as of October 2026), CVS trades at 10.82x and OPCH at 14.98x, so CVS is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both CVS and OPCH?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of CVS vs OPCH?
+
CVS: The clearest risk is the medical-cost trend at Aetna: if claims reaccelerate, especially in Medicare Advantage, earnings can fall faster than premiums can be re-priced, which is what drove the 2023 to 2024 decline. The Caremark PBM faces intensifying regulatory and political pressure, including FTC litigation, a 2026 House Judiciary antitrust report, state investigations in Florida and elsewhere, and rebate pass-through reform that could compress a core profit pool. Legal costs continue: in October 2026 CVS agreed to a $315 million settlement of federal claims over opioid dispensing, with new controlled-substance oversight measures. The retail pharmacy business faces reimbursement pressure and store closures, and the company carries about $76 billion of debt, much of it from the Aetna deal, which limits flexibility if the turnaround stalls. OPCH: The central risk is deal risk. The take-private requires Option Care shareholder approval and regulatory approvals, and a combination involving a major drug distributor could draw antitrust scrutiny; a legal review of the proposed takeover has also been reported. If the deal broke, the shares could fall back toward pre-announcement levels, since the 37% premium is what lifted them. The upside is effectively capped near $32.05 while the deal is pending, and the time to an expected first-half 2027 close ties up capital. The underlying business risks still matter if the deal fails: the CID drug-portfolio headwind tied to Stelara and biosimilar transitions, thin gross margins (about 19%) on high drug pass-through revenue, sensitivity to reimbursement and payer contract terms, competition from CVS Coram and Optum-affiliated Naven Health, and about $1.27 billion of debt against roughly $197 million of cash.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CVS or OPCH; figures are approximate and dated (as of October 2026). Verify current data before investing.